UPDATE: Canaccord Genuity Starts Celgene (CELG) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
BMO Capital Positive on Celgene (CELG) REVLIMID Label Expansion
February 18, 2015 2:13 PM ESTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $163 price target on Celgene (NASDAQ: CELG) saying the REVLIMID label expansion in the U.S. should support continued growth.
Birchenough commented, "We are reiterating our Outperform rating on shares of the CELG... More
Celgene (CELG) Confirms No IPRs Filed; BofA/Merrill Lynch Sees Strong Revlimid Patents
February 18, 2015 6:50 AM ESTBofA/Merrill Lynch analyst Ying Huang reiterated a Buy rating and $136 price target on Celgene (NASDAQ: CELG) after the company confirmed that no Inter Partes Reviews (IPRs) have been filed to date on any of its products, including Revlimid and Pomalyst. Management also... More
